EMOTIon and COgNitive Function After Atrial Fibrillation Catheter Ablation vs. Medical Therapy(EMOTICON Trial)
EMOTIon and COgNitive Function After Atrial Fibrillation Catheter Ablation vs. Medical Therapy; Randomized Clinical Trial (EMOTICON Trial)
"Atrial fibrillation (AF) is an arrhythmic disease that increases especially in the elderly, increasing the risk of ischemic stroke by 5 times and is a major cause of dementia and cognitive impairment.
Cognitive dysfunction accompanying AF occurs regardless of the presence or absence of stroke, and AF itself is known to affect cognitive function.
However, since cognitive dysfunction is also affected by various accompanying chronic diseases, whether the cognitive dysfunction accompanying AF is due to subclinical ischemic stroke, cerebral hypoperfusion due to reduced cardiac output, inflammatory reaction or platelet dysfunction are unclear.
Recently, this research team reported an improvement in cognitive function with active sinus rhythm therapy such as AF catheter ablation. Nevertheless, it has not yet been proven whether such active and invasive AF treatment affects the improvement of cognitive function or depression by a randomized clinical trial.
In this prospective randomized clinical comparative study, the investigators will compare the AF catheter ablation group and drug therapy group in terms of cognitive function tests and depression psychological tests at baseline and a year after treatment. Our hypothesis is that AF catheter ablation is superior to drug therapy to improve cognitive function and depressive mood.
研究概览
详细说明
Study design
- Prospective randomization (catheter ablation group vs. drug treatment group) (Python program is used, the random number module is imported using the import random syntax, and the random number table of the two groups is prepared and used)
- Target number of targets 320 (160 for each group)
- Cardiac rhythm follow-up: 2012 ACC/AHA/ESC guidelines (baseline, 3 months, every 6 months after Holter, Electrocardiogram when symptoms are present)
- Anticoagulant therapy follows 2014 ACC/AHA/ESC guidelines.
- Evaluation of MOCA score (cognitive function), CES-D score (depression), and GAD-7 score (anxiety) at baseline and a year after treatment, respectively.
- Evaluation of all adverse events occurring in each group, hospitalization rate, major cardiovascular attack, and mortality rate comparison
Progress and rhythm/ ECG follow-up
- Implemented in accordance with 2012 ACC/AHA/HRS guidelines for AF management
- Baseline MOCA, CES-D, and GAD-7 score evaluation
- Outpatient follow-up observation 1 to 2 weeks after the start of the procedure or medication
- Follow-up observation at intervals of 2 months, 6 months, and then every 6 months after starting the procedure or medication
- If the patient complains of arrhythmia symptoms, conduct an electrocardiogram at any time, and follow the rhythm with a Holter or event recorder.
- Follow-up MOCA, CES-D, and GAD-7 score evaluation
Follow-up observation
- All patients are scheduled to visit the outpatient clinic every 6 months after 1~2 weeks, 2 months, 6 months, and even if they have symptoms in the middle, they will be treated as an outpatient at any time.
- An ECG is administered at every outpatient visit. A 24-hour Holter or event recorder was administered for 1 year at intervals of 2, 6, and 6 months after the procedure (2012 Heart Rhythm Society/EHRA/European Cardiac Arrhythmia Society Expert Consensus Statement guidelines).
- If atrial fibrillation or atrial tachycardia lasting more than 30 seconds is observed on a standard electrocardiogram, event electrocardiogram, or Holter, it is evaluated as recurrence. Recurrence within 3 months after the procedure is classified as early recurrence, and recurrence after 3 months is classified as clinical recurrence.
研究类型
注册 (预期的)
阶段
- 不适用
联系人和位置
学习地点
-
-
-
Seoul、大韩民国
- Yonsei University Health system, Severance Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Patients aged between 20 and 80 years of age who have appropriate indication for catheter ablation for AF
- AF patients with left atrium diameter <55 mm
- Antiarrhythmic drug-resistant AF
- Anticoagulation eligible patients
Exclusion Criteria:
- AF associated with severe cardiac malformation or structural heart disease
- Patients undergoing treatment for cognitive disorders, emotional disorders, and anxiety disorders
- Patients with severe renal dysfunction or difficulty in CT imaging using contrast media
- Patients with a previous history of AF ablation or other open heart surgery
- Patients with active internal bleeding
- Anticoagulant therapy not eligible patients
- Valvular AF (mitral valve stenosis>grade 2, mechanical valve, mitral valve reconstruction)
- Significant comorbidities
- Patients with an expected survival period of less than 1 year
- Drug or alcohol addiction patients
- Among eligible persons, those who cannot read the consent form (illiteracy, foreigners, etc.)
- Patients judged to be unsuitable for participation in clinical research based on the judgment of other researchers
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Atrial fibrillation catheter ablation group
catheter ablation
|
|
有源比较器:Medical therapy group
standard treatment include anti-arrhythmic drug
|
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Changes in cognitive function, depression, and anxiety scale after catheter ablation or drug treatment after 1 year of randomization
大体时间:1 year
|
Compasison of scale change using the Moca questionnaire.
|
1 year
|
Changes in depression scale after catheter ablation or drug treatment after 1 year of randomization
大体时间:1 year
|
Compasison of scale change using the CES-D questionnaire.
|
1 year
|
Changes in anxiety scale after catheter ablation or drug treatment after 1 year of randomization
大体时间:1 year
|
Compasison of scale change using the GAD-7 questionnaire.
|
1 year
|
次要结果测量
结果测量 |
大体时间 |
---|---|
Differences according to AF type
大体时间:1year
|
1year
|
Differences in adverse effects of ablation vs. medications
大体时间:1year
|
1year
|
Differences in MACE, Death, and Readmission rate
大体时间:1year
|
1year
|
合作者和调查者
调查人员
- 首席研究员:Hui-Nam Pak、Yonsei University
研究记录日期
研究主要日期
学习开始 (预期的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.